Access Pharmaceuticals, a biopharmaceutical company specializing in products for cancer and supportive care, announced today the signing of an agreement with BioScrip (NASDAQ: BIOS) for the distribution of MuGard, the lead product of Access. MuGard is an FDA approved oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy. The agreement provides for the distribution of MuGuard through BioScrip’s nationwide distribution platform, including 110 BioScrip specialty pharmacies. It also allows Access to leverage BioScrip’s extensive physician relationships, and provides for mail distribution and a diversified payor network.
BioScrip is a national provider of specialty pharmacy and home care products and services, working with patients, physicians, hospitals, healthcare payors, and pharmaceutical manufacturers. Access VP of Sales and Marketing, Frank Jacobucci, spoke of the significance of the BioScrip agreement. “As one of the largest, top-tier players in this space, BioScrip is well-established, reputable and focused on tailoring its programs to best fit and meet product manufacturers, provider and payers and patients’ pharmacy service needs. In addition to the varied services that they will provide us, this partnership also results in multiple delivery options for patients in need of MuGard, including overnight delivery, home delivery and live retail pharmacy sites in the top metropolitan areas. We believe offering various methods of receiving MuGard can significantly increase patient compliance and ultimately provide an important additional weapon to help improve the treatment outcome.”
Access CEO, Jeffrey Davis, said, “Signing a strong specialty distribution partner is a critical milestone for a successful entrance into the US market. With its significant resources, deep capabilities and strong commitment to cancer patients, BioScrip is an ideal partner to have in place as we continue executing on our global-commercialization strategy for MuGard.”
BioScrip VP of Trade Relations and Business Development, Scott Friedman, said, “BioScrip is proud to have been selected by Access to be its exclusive distribution and service partner for MuGard. Our vast clinical, sales and operational specialty pharmacy assets, combined with our deep oncology experience, put us in a unique position to provide services to the patient, manufacturer, provider and payor communities.”
For additional information on Access Pharmaceuticals, visit www.AccessPharma.com.
Let us hear your thoughts below: